Active portfolio companies
|
7TM Pharma A/S is focused on discovery and development of new drugs targeting 7TM receptors. Its primary therapeutic area is metabolic diseases, including obesity, diabetes and cardiovascular diseases. Novo A/S board representative: Søren Carlsen |
|||
|
|
|||
|
Alios BioPharma, Inc. is developing novel treatments against viral diseases. Its lead program is in preclinical development and is aimed at oral small molecules that activate a key part of the interferon pathway. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
AlloCure Inc. is dedicated to developing adult stem cell therapies. Its most advanced compound is in phase 1 clinical development and is in the field of acute renal failure. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Amira Pharmaceuticals, Inc. is focused on discovery and early development of novel small molecule drugs to treat inflammatory diseases. Its lead compound is in phase 2 clinical development and is partnered with GSK for the treatment of respiratory and cardiovascular disease. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
AnaptysBio, Inc. is discovering and optimising therapeutic antibodies using somatic hypermutation and flow cytometry to create 'naturalised' antibodies with superior bioactivities. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
BioMimetic Therapeutics, Inc. (BMTI, NASDAQ) is developing and commercialising drug device combination products for the repair of orthopaedic injuries to bone, cartilage, ligaments and tendons. Novo A/S board representative: Thorkil Kastberg Christensen |
|||
|
|
|||
|
Cell Biosciences, Inc. developing instruments to enable the detection of specific proteins and isoforms in extremely small biological samples. Its lead product was launched in 2008. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
Celltrix AB is developing injectable dermal filler for reconstructive cosmetic surgery, based on microbeads of cross-linked gelatine. Its lead compound Credurance is in clinical development. |
|||
|
|
|||
|
Cytochroma Inc. is developing and commercialising products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). It has several compounds in late stage clinical development. Novo A/S board representative: Peter Moldt |
|||
|
|
|||
|
f-star GmbH is developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology. Its lead compound is in preclinical development. Novo A/S board representative: Kim L. Dueholm |
|||
|
|
|||
|
Funxional Therapeutics Ltd is focused on broad-spectrum chemokine inhibitors for a broad range of inflammatory conditions. Its small molecule lead candidate is in phase 1 clinical development. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Inogen, Inc. is developing, manufacturing and marketing lightweight, portable oxygen therapy devices to improve quality of life and increase mobility for patients with Chronic Obstructive Pulmonary Disease. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
LifeCycle Pharma A/S (LCP, OMX) has two products in late stage clinical development based on a novel drug delivery platform. The company’s first product was approved by the FDA in 2008. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
Light Sciences Oncology, Inc. is in the final stages of clinical trials of Aptocine™, a drug activated by a disposable drug activator for the treatment of solid tumors as well as other indications including benign prostatic hyperplasia (BPH). Novo A/S board representative: Peter Bisgaard |
|||
|
|
|||
|
Logical Therapeutics, Inc. is developing medicines to treat inflammatory diseases. Its lead compound, a naproxen pro-drug, is in phase 2 clinical development for the treatment of osteoarthritis. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Lux Biosciences, Inc. is dedicated to the development and commercialisation of pharmaceutical products for the treatment of ophthalmic diseases. Lux has two compounds in late stage clinical development. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
M2 Medical, Inc. is developing and marketing easy-to-use, disposable insulin pumps that are both affordable and reliable. Novo A/S board representative: Peter Bisgaard |
|||
|
|
|||
|
MediQuest Therapeutics, Inc. is focused on treatments and delivery systems directed against skin diseases. Its lead product is in late stage clinical development for the prevention and treatment of Raynaud’s Disease. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
Metabolex, Inc. is discovering and developing novel therapeutics to treat diabetes and related metabolic disorders. Its lead programs are in phase 2 clinical development. |
|||
|
|
|||
|
NeoMend, Inc. develops products that facilitate sealing and healing of soft tissue wounds. NeoMend filed a PMA with the FDA for its most advanced product. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
NeuroTherapeutics Pharma, Inc. NeuroTherapeutics Pharma, Inc. is focused on developing novel small molecule therapeutics for diseases associated with CNS hyperexcitability, including epilepsy and pain. Its lead candidate is in preclinical development. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
Nuevolution A/S utilises its Chemetics® technology to synthesise and identify drug leads. |
|||
|
|
|||
|
Ophthotech Corporation is focused on developing improved therapies for dry and wet Age-related Macular Degeneration. Its lead compounds are in phase 1 clinical development. Novo A/S board representative: Thomas Dyrberg |
|||
|
|
|||
|
PTC Therapeutics, Inc. discovers and develops small molecule drugs that modulate gene expression by selectively binding to RNA targets. Its most advanced product is in phase 2 clinical development for cystic fibrosis and Duchenne muscular dystrophy. Novo A/S board representative: Søren Carlsen |
|||
|
|
|||
|
Reata Pharmaceuticals, Inc. is developing new drugs for the treatment of cancer, inflammation and kidney diseases. Its lead program is in clinical development for Chronic Kidney Disease. Novo A/S board representative: Jack B. Nielsen |
|||
|
|
|||
|
Santaris Pharma A/S is developing new RNA antagonist drugs against metabolic disorders and viral disease. The technology is also being developed for products targeting micro-RNA. Novo A/S board representative: Søren Carlsen |
|||
|
|
|||
|
Serentis Ltd is developing and commercialising proprietary medicinal products in the areas of dermatology. It has two products in phase 2 clinical development. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Symphogen A/S is developing recombinant human polyclonal antibodies. The lead compound is in phase 2 clinical development for the treatment of idiopathic thrombocytopenic purpura and prevention of hemolytic disease of newborns. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Synosia Therapeutics develops and intends to commercialise innovative products for unmet medical needs in psychiatry and neurology. Its product pipeline includes seven clinical stage compounds acquired through strategic partnerships with Roche, Novartis and Syngenta. Novo A/S board representative: Heath Lukatch |
|||
|
|
|||
|
Tarsa Therapeutics Inc. is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction. Its calcitionin product is in phase 3 clinical development. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Vantia Therapeutics, Ltd. has two clinical stage products, one for the symptomatic treatment of nocturia in men with enlarged prostate glands and one for the treatment of dysmenorrhoea, as well as several preclinical programs. Novo A/S board representative: Martin Edwards |
|||
|
|
|||
|
Xenon Pharmaceuticals Inc. is a genetics-based drug development company, discovering innovative drugs. Its lead compound is in clinical studies for the treatment of pain. |
|||
|
|
|||
|
ZymoGenetics, Inc. (ZGEN, NASDAQ) focuses on discovery, development and commercialisation of therapeutic proteins. Its first product RECOTHROM® was launched in partnership with Bayer Healthcare in 2008. |
|||
|
|
|||